Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
Experience in Evaluating Drug Efficacy in a Bleomycin-Induced IPF Model
Today, we would like to introduce the modalities and target molecules that we have experience in evaluating drug efficacy in our bleomycin-induced IPF model. SMC Laboratories has over 150 studies of experience in conducting IPF studies. As shown in the figure below, we have experience with test substances of various modalities, including small molecules,…
2025.02.01
Histopathological Analysis Service
We would like to introduce on our histopathological analysis service. Recently, we have received many inquiries from our clients regarding histopathological analysis, such as “We have conducted in vivo studies, but we are having trouble with histopathological analysis,” or ” We need analysis data evaluated by a third-party.” We have accumulated experience and…
2025.01.31
MASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around the world, the prevalence of NAFLD has now increased to 30%, and it is expected to continue to increase [Younossi Z et al., Hepatology. 2023]. One of the risks of NAFLD is its ability to progress to other…
2025.01.30
[ Consultations are increasing! ] The first step to accelerate MASH research
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. FDA approved first MASH treatment If you are developing a MASH treatment drug under these circumstances, by first contacting a specialized CRO, you will be…
2025.01.30
Introducing a preclinical model for Alzheimer’s disease
We would like to introduce you to an Alzheimer’s disease model. –About Alzheimer’s disease Alzheimer’s disease is a progressive neurodegenerative condition that currently has no cure and accounts for the majority of dementia cases. It is characterized by an accumulation of amyloid-beta, the main pathogen, in the brain and neuronal cell death due to…
2025.01.30
Introduction of Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis Mouse Model
Today, we would like to briefly share with you a typical pathological mouse model of Inflammatory Bowel Disease (IBD), the Dextran Sodium Sulfate (DSS)-induced Chronic Colitis Model. The characteristics of the DSS-induced chronic colitis model are as follows: – Simple and reproducible disease induction method – Short disease induction period – Intestinal fibrosis such…
2025.01.30
Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that starting today we are expanding our preclinical services and adding the “Imiquimod (IMQ)-induced dermatitis model“, a mouse model for psoriasis, to our lineup. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of…
2025.01.30
Silica-induced pulmonary fibrosis model
We would like to introduce the “Silica-induced pulmonary fibrosis model“. Pulmonary fibrosis in silica models occurs early and is maintained long term. Hence, this model is one of the most beneficial model mice for therapeutic study for pulmonary fibrosis. In general, human pulmonary fibrosis does not resolve, whereas fibrosis in bleomycin model, a typical…
2025.01.30
Anti-Angiogenic Drug for HCC: STAM model
We would like to focus on Hepatocellular Carcinoma (HCC). Tumor angiogenesis plays a crucial role in supplying a tumor with oxygen and nutrients to sustain optimal growth. As HCC is a typical hypervascular tumor that forms a network of blood vessels, inhibiting tumor angiogenesis is expected to be useful in the treatment of HCC….
2025.01.30
Introduction to the hepatocellular carcinoma model (DEN-CCl4 model)
We would like to introduce the DEN-CCl4 mouse model for hepatocellular carcinoma (HCC). We focus on key pathophysiological events of human cirrhosis-associated hepatocarcinogenesis and have selected the DEN-CCl4 mouse model where chronic liver fibrosis leads to dramatic potentiation of the liver tumor incidence, with 100% of mice developing liver tumors at 30 weeks of…
We can help you advance your research.